Published in Oncogene on November 28, 2016
Epigenetic Basis of Cancer Health Disparities: Looking Beyond Genetic Differences. Biochim Biophys Acta (2017) 0.76
MicroRNAs: target recognition and regulatory functions. Cell (2009) 92.17
Prediction of mammalian microRNA targets. Cell (2003) 53.70
Combinatorial microRNA target predictions. Nat Genet (2005) 50.48
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A (2004) 28.29
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov (2012) 26.98
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal (2013) 19.54
Gene expression correlates of clinical prostate cancer behavior. Cancer Cell (2002) 16.27
The microRNA.org resource: targets and expression. Nucleic Acids Res (2007) 16.26
Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res (2005) 13.89
Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A (2004) 10.99
MicroRNA expression profiling in prostate cancer. Cancer Res (2007) 8.04
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res (2006) 7.61
The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med (2011) 6.85
American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin (2010) 6.45
Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res (2005) 5.87
Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene (2006) 5.86
Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev (2010) 5.83
The Molecular Taxonomy of Primary Prostate Cancer. Cell (2015) 3.29
Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res (2007) 3.13
Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells. Cancer Res (2007) 3.00
PC3 human prostate carcinoma cell holoclones contain self-renewing tumor-initiating cells. Cancer Res (2008) 2.16
Integrative analysis of genomic aberrations associated with prostate cancer progression. Cancer Res (2007) 2.14
Regulatory Role of mir-203 in Prostate Cancer Progression and Metastasis. Clin Cancer Res (2010) 2.07
Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNP. Cancer Res (2003) 1.99
Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res (1993) 1.96
Prostate cancer stem/progenitor cells: identification, characterization, and implications. Mol Carcinog (2007) 1.74
MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway. Carcinogenesis (2012) 1.58
Evidence for three tumor suppressor gene loci on chromosome 8p in human prostate cancer. Cancer Res (1995) 1.38
Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer. Clin Cancer Res (2009) 1.31
Downregulation of microRNA-383 is associated with male infertility and promotes testicular embryonal carcinoma cell proliferation by targeting IRF1. Cell Death Dis (2010) 1.18
MicroRNAs 373 and 520c are downregulated in prostate cancer, suppress CD44 translation and enhance invasion of prostate cancer cells in vitro. Int J Clin Exp Pathol (2008) 1.16
miRNA-708 control of CD44(+) prostate cancer-initiating cells. Cancer Res (2012) 1.16
Homozygous deletions at 8p22 and 8p21 in prostate cancer implicate these regions as the sites for candidate tumor suppressor genes. Oncogene (1995) 1.07
Prostate cancer stem cells and their potential roles in metastasis. J Surg Oncol (2011) 0.98
Prostate cancer screening 2010: updated recommendations from the American Cancer Society. J Natl Med Assoc (2010) 0.98
Transactivation of micrornA-320 by microRNA-383 regulates granulosa cell functions by targeting E2F1 and SF-1 proteins. J Biol Chem (2014) 0.96
Clinical significance of chromosome 8p, 10q, and 16q deletions in prostate cancer. Prostate (2003) 0.94
microRNA-383 impairs phosphorylation of H2AX by targeting PNUTS and inducing cell cycle arrest in testicular embryonal carcinoma cells. Cell Signal (2014) 0.88
Cell adhesion molecule CD44: its functional roles in prostate cancer. Am J Transl Res (2010) 0.86
Downregulation of miR-383 promotes glioma cell invasion by targeting insulin-like growth factor 1 receptor. Med Oncol (2013) 0.86
PSA and beyond: alternative prostate cancer biomarkers. Cell Oncol (Dordr) (2016) 0.86
MicroRNA-383 inhibits anchorage-independent growth and induces cell cycle arrest of glioma cells by targeting CCND1. Biochem Biophys Res Commun (2014) 0.86
Allelotyping analysis at chromosome arm 8p of high-grade prostatic intraepithelial neoplasia and incidental, latent, and clinical prostate cancers. Genes Chromosomes Cancer (2006) 0.85
MicroRNA-383 regulates the apoptosis of tumor cells through targeting Gadd45g. PLoS One (2014) 0.83
ROBO3 promotes growth and metastasis of pancreatic carcinoma. Cancer Lett (2015) 0.82
MicroRNA-383 expression regulates proliferation, migration, invasion, and apoptosis in human glioma cells. Tumour Biol (2015) 0.81
Stemming a tumor with a little miR. Nat Med (2011) 0.81
Haploinsufficiency of 8p22 may influence cancer-specific survival in prostate cancer. Cancer Genet Cytogenet (2007) 0.77
The role of chromosome 8p22 deletion for predicting disease progression and pathological staging in prostate cancer. Aktuelle Urol (2003) 0.76
STAT3 regulated ATR via microRNA-383 to control DNA damage to affect apoptosis in A431 cells. Cell Signal (2015) 0.76
De novo 1Mb interstitial deletion of 8p22 in a patient with slight mental retardation and speech delay. Mol Cytogenet (2014) 0.75